Effect of Astragali Radix-Curcumae Rhizoma compatibility combined with 5-fluorouracil on Th17/Treg balance and tumor-related mRNA and protein expression in orthotopic xenograft model mice of CT26.WT colorectal carcinoma.
10.19540/j.cnki.cjcmm.20211008.401
- Author:
Wen-Hui GUO
1
;
Zhuo-Cao QI
2
;
Han-Qing GUAN
1
;
Tian-Tian LIU
1
;
Li LIANG
1
;
Qian-Hui YU
1
;
Yan LIANG
1
;
De-Cai TANG
1
Author Information
1. School of Traditional Chinese Medicine·School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China.
2. School of Traditional Chinese Medicine·School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China Basic Medical College, Shanghai University of Chinese Medicine Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
Astragali Radix;
Curcumae Rhizoma;
IFN-γ;
TGF-β;
TNF-α;
Th17/Treg;
colon cancer
- MeSH:
Animals;
Colorectal Neoplasms/genetics*;
Drugs, Chinese Herbal/pharmacology*;
Fluorouracil/pharmacology*;
Heterografts;
Humans;
Male;
Mice;
Mice, Inbred BALB C;
RNA, Messenger/metabolism*;
T-Lymphocytes, Regulatory;
Th17 Cells
- From:
China Journal of Chinese Materia Medica
2022;47(1):167-175
- CountryChina
- Language:Chinese
-
Abstract:
Astragali Radix-Curcumae Rhizoma(AR-CR) is a combination commonly used in the clinical treatment of tumors. Based on the T helper 17(Th17)/regulatory T cell(Treg) balance, the present study explored the possible mechanism of AR-CR combined with 5-fluorouracil(5-FU) on the tumor growth of orthotopic xenograft model mice of colorectal carcinoma. Ninety male BALB/c mice were randomly divided into nine groups, i.e., a blank group, a model group, a 5-FU group, high-, medium-, and low-dose AR-CR(2∶1) groups, and high-, medium-, and low-dose AR-CR+5-FU groups, with 10 mice in each group. The orthotopic xenograft model of CT26.WT colorectal carcinoma was induced in mice except those in the blank group. Twenty-four hours after the ope-ration, mice in the blank group and the model group received normal saline by gavage(10 mL·kg~(-1), once per day), and those in the 5-FU group received 5-FU by intraperitoneal injection(25 mg·kg~(-1), once every other day). Mice in the AR-CR groups received AR and CR decoctions by gavage(12, 6, and 3 g·kg~(-1), once a day) and those in the combination groups received AR and CR decoctions and 5-FU(doses and administration methods were the same as above). After intervention for three weeks, all mice were sacrificed and tumor tissues were collected. The tumor mass was weighed and the average tumor weight was calculated. The changing trend of Th17/Treg(%) in the CD4~+T lymphocytes of the spleen tissues of the mice in each group was detected. The mRNA expression in the blood and protein expression in the tumor tissues of transforming growth factor-β(TGF-β), tumor necrosis factor-α(TNF-α), interferon-γ(IFN-γ), Smad4, N-cadherin, matrix metalloproteinase-7(MMP-7) were detected. The experimental results revealed that compared with the model group, the groups with drug intervention showed reduced tumor mass(P<0.01), decreased CD4~+IL-17~+ in the spleen tissues to varying degrees(P<0.001), and increased proportion of CD4~+Foxp3~+(P<0.001 or P<0.05), indicating that Th17/Treg maintained dynamic balance, and the effect of the combination groups was predominant. Additionally, the mRNA expression in the blood and protein expression in the tumor tissues of TGF-β, TNF-α, IFN-γ, Smad4, N-cadherin, and MMP-7 declined to varying degrees in a dose-dependent manner(P<0.01 or P<0.001). The AR-CR combined with 5-FU can inhibit the tumor growth of orthotopic xenograft model mice of CT26.WT colorectal carcinoma. The mechanism may be related to maintenance of Th17/Treg dynamic balance in the body and down-regulation of TGF-β, TNF-α, IFN-γ, Smad4, N-cadherin, and MMP-7 expression.
